Stem definition | Drug id | CAS RN |
---|---|---|
cyclin dependant kinase inhibitors | 5442 | 1374743-00-6 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 12, 2021 | FDA | G1 THERAPEUTICS Inc |
None
None
None
None
Source | Code | Description |
---|---|---|
ATC | V03AF12 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Detoxifying agents for antineoplastic treatment |
FDA EPC | N0000175605 | Kinase Inhibitor |
FDA MoA | N0000187061 | Organic Cation Transporter 2 Inhibitors |
FDA MoA | N0000191423 | Multidrug and Toxin Extrusion Transporter 1 Inhibitors |
FDA MoA | N0000193921 | Cyclin-dependent Kinase 4 Inhibitors |
FDA MoA | N0000193922 | Cyclin-dependent Kinase 6 Inhibitors |
FDA MoA | N0000193932 | Multidrug and Toxin Extrusion Transporter 2 K Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Chemotherapy-induced myelosuppression | indication | 370569000 | |
Extensive-stage small cell lung cancer | indication | 458321000124102 |
None
None
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 300MG BASE/VIAL | COSELA | G1 THERAP | N214200 | Feb. 12, 2021 | RX | POWDER | INTRAVENOUS | 10085992 | March 14, 2034 | A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A CARBOPLATIN AND ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER |
EQ 300MG BASE/VIAL | COSELA | G1 THERAP | N214200 | Feb. 12, 2021 | RX | POWDER | INTRAVENOUS | 10966984 | March 14, 2034 | A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER |
EQ 300MG BASE/VIAL | COSELA | G1 THERAP | N214200 | Feb. 12, 2021 | RX | POWDER | INTRAVENOUS | 10966984 | March 14, 2034 | A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE- STAGE SMALL CELL LUNG CANCER |
EQ 300MG BASE/VIAL | COSELA | G1 THERAP | N214200 | Feb. 12, 2021 | RX | POWDER | INTRAVENOUS | 9487530 | March 14, 2034 | A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER |
EQ 300MG BASE/VIAL | COSELA | G1 THERAP | N214200 | Feb. 12, 2021 | RX | POWDER | INTRAVENOUS | 9487530 | March 14, 2034 | A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE- STAGE SMALL CELL LUNG CANCER |
EQ 300MG BASE/VIAL | COSELA | G1 THERAP | N214200 | Feb. 12, 2021 | RX | POWDER | INTRAVENOUS | 11529352 | July 23, 2039 | A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN THAT INCLUDES AN IMMUNE CHECKPOINT INHIBITOR FOR EXTENSIVE-STAGE SMALL CELL CANCER |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 300MG BASE/VIAL | COSELA | G1 THERAP | N214200 | Feb. 12, 2021 | RX | POWDER | INTRAVENOUS | Feb. 12, 2026 | NEW CHEMICAL ENTITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Cyclin-dependent kinase 6 | Kinase | INHIBITOR | IC50 | 8.40 | DRUG LABEL | DRUG LABEL | |||
Cyclin-dependent kinase 4 | Kinase | INHIBITOR | IC50 | 9 | DRUG LABEL | DRUG LABEL | |||
Cyclin-dependent kinase 2 | Kinase | INHIBITOR | IC50 | 5.72 | DRUG LABEL | ||||
Cyclin-dependent-like kinase 5 | Kinase | INHIBITOR | IC50 | 5.83 | DRUG LABEL | ||||
Cyclin-dependent kinase 9 | Kinase | INHIBITOR | IC50 | 7.30 | DRUG LABEL | ||||
Receptor-type tyrosine-protein kinase FLT3 | Kinase | INHIBITOR | Kd | 9.15 | DRUG LABEL | ||||
NUAK family SNF1-like kinase 2 | Kinase | INHIBITOR | Kd | 9.15 | DRUG LABEL | ||||
Serine/threonine-protein kinase Nek10 | Kinase | INHIBITOR | Kd | 9.57 | DRUG LABEL | ||||
Cyclin-dependent kinase 7 | Kinase | INHIBITOR | IC50 | 5.33 | DRUG LABEL | ||||
Cyclin-dependent kinase 1 | Kinase | INHIBITOR | IC50 | 5.53 | DRUG LABEL |
ID | Source |
---|---|
D11130 | KEGG_DRUG |
U6072DO9XG | UNII |
1977495-97-8 | SECONDARY_CAS_RN |
C4524320 | UMLSCUI |
CHEMBL3894860 | ChEMBL_ID |
68029831 | PUBCHEM_CID |
DB15442 | DRUGBANK_ID |
CHEMBL4650272 | ChEMBL_ID |
9626 | IUPHAR_LIGAND_ID |
018637 | NDDF |
018638 | NDDF |
1149152001 | SNOMEDCT_US |
1149273007 | SNOMEDCT_US |
1149274001 | SNOMEDCT_US |
4040108 | VANDF |
2479690 | RXNORM |
343885 | MMSL |
39327 | MMSL |
d09715 | MMSL |
C000708352 | MESH_SUPPLEMENTAL_RECORD_UI |
10565 | INN_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Cosela | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73462-101 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 300 mg | INTRAVENOUS | NDA | 26 sections |
Cosela | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73462-101 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 300 mg | INTRAVENOUS | NDA | 26 sections |